TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33420673

Group type: COMPARATOR
Intervention: Continuous Energy Restriction (CER) - average daily energy deficit of 500 kcal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet (FMD) - 5-day low energy, sugars, and proteins, high in unsaturated fats
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous Energy Restriction (CER)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet (FMD)
Number of subjects: 60
Study: 32316007

Group type: EXPERIMENTAL
Intervention: Unilateral left thalamic stimulation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bilateral thalamic DBS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Left hemisphere stimulation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Right hemisphere stimulation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both sides on, left side on, right side on, both sides off
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bilateral approach recommended for future studies
Number of subjects: 8
Study: 35881208

Group type: EXPERIMENTAL
Intervention: MLS laser as a manual scanning technique (10 J/cm2, area 50cm2, total energy 500 J)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MLS laser using point application technique (10 J/point, 8 points, total 80 J)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 60
Study: 34393739

Group type: EXPERIMENTAL
Intervention: Upper extremity group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lower extremity group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 37
Study: 32469084

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation training
Number of subjects: 107

Group type: COMPARATOR
Intervention: Classical training on the management of pre-eclampsia
Number of subjects: 107
Study: 34299972

Group type: EXPERIMENTAL
Intervention: Psychoeducation-enriched care for family members
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard Indonesian mental healthcare (Control)
Number of subjects: 64
Study: 36352445

Group type: EXPERIMENTAL
Intervention: Tablet-based video game stimulating cognitive and socio-emotional skills
Number of subjects: 750

Group type: COMPARATOR
Intervention: Tablet-based game where students draw and paint (control)
Number of subjects: 750
Study: 34477455

Group type: EXPERIMENTAL
Intervention: Method of estimating sample size for a main cluster-randomised trial with a continuous outcome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upper confidence limit method for sample size calculation
Number of subjects: 0
Study: 32310260

Group type: EXPERIMENTAL
Intervention: Multicomponent delirium prevention intervention
Number of subjects: 10
Study: 36130745

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) blockade with multimodal analgesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo ESP blockade with multimodal analgesia
Number of subjects: 50
Study: 33228739

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 2 mL/kg of 20% intralipid before aortic cross-unclamping
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Normal saline (equivalent volume to intralipid)
Number of subjects: 1000
Study: 35422138

Group type: EXPERIMENTAL
Intervention: Diet rich in monounsaturated fatty acids
Number of subjects: 27548

Group type: EXPERIMENTAL
Intervention: Diet rich in n-6 polyunsaturated fatty acids
Number of subjects: 27548

Group type: COMPARATOR
Intervention: Control diet rich in saturated fatty acids
Number of subjects: 27548
Study: 34154367

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (4 g daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study: 35614404

Group type: EXPERIMENTAL
Intervention: Home‐Based Multimodality Functional Recovery and Metabolic Health Enhancement Program (FES‐LC plus AE and testosterone therapy)
Number of subjects: 88

Group type: COMPARATOR
Intervention: FES‐LC plus AE and placebo injections
Number of subjects: 88
Study: 34064372

Group type: EXPERIMENTAL
Intervention: Animal fat intake
Number of subjects: 146

Group type: COMPARATOR
Intervention: Normal levels of albuminuria
Number of subjects: 146
Study: 33580174

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation program with remote electrocardiographic monitoring (n=33)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Traditional hospital-based cardiac rehabilitation program (n=38)
Number of subjects: 71
Study: 33124654

Group type: EXPERIMENTAL
Intervention: Pharmacist/Clinician Collaborative (PCC) group (n = 496)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Usual Care (UC) group (n = 500)
Number of subjects: 996
Study: 33291054

Group type: EXPERIMENTAL
Intervention: c-MeST program
Number of subjects: 245

Group type: COMPARATOR
Intervention: wait-list control group
Number of subjects: 245
Study: 32980696

Group type: EXPERIMENTAL
Intervention: intermittent theta‐burst stimulation (iTBS) targeting the left DLPFC
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: continuous theta‐burst stimulation (cTBS) targeting the left vmPFC
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: combination of treatment protocol of Group A and Group B
Number of subjects: 74

Group type: COMPARATOR
Intervention: sham theta‐burst stimulation
Number of subjects: 74
Study: 33172409

Group type: EXPERIMENTAL
Intervention: Pre-hospital assessment by Emergency Nurses (PENs)
Number of subjects: 4587
Study: 35302389

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32885470

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 26715

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 26715
Study: 35157781

Group type: EXPERIMENTAL
Intervention: Levetiracetam granules (500 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral solution of levetiracetam
Number of subjects: 24
Study: 34506883

Group type: EXPERIMENTAL
Intervention: Dietary dandelion flower extract (DFE) at 3 g/kg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dietary dandelion flower extract (DFE) at 2 and 3 g/kg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dietary dandelion flower extract (DFE) at 3 and 4 g/kg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (0 g/kg DFE)
Number of subjects: 300
Study: 33241157

Group type: EXPERIMENTAL
Intervention: High-velocity low-amplitude (HVLA) manipulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Muscle energy techniques (MET)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 33836265

Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus prednisone (group A)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Physician's choice of enzalutamide or abiraterone plus prednisone (group B)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Baseline circulating tumour DNA (ctDNA) fraction above the cohort median
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: On-treatment ctDNA increase
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: ctDNA fraction >30% at baseline
Number of subjects: 95
Study: 33327947

Group type: EXPERIMENTAL
Intervention: Video-based, student tutor-led course (ViST)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Faculty staff-led course (FS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Video questionnaire for AU
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Video questionnaire for TTE
Number of subjects: 96
Study: 35151715

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) - 26 Gy in 2 weekly fractions
Number of subjects: 113

Group type: COMPARATOR
Intervention: High dose rate (HDR) brachytherapy - 27 Gy in 2 weekly fractions
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 113

Group type: COMPARATOR
Intervention: HDR
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SABR and HDR
Number of subjects: 113
Study: 33646021

Group type: EXPERIMENTAL
Intervention: General disinformation media literacy education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deepfake-specific media literacy education
Number of subjects: 0

Group type: COMPARATOR
Intervention: No media literacy education
Number of subjects: 0
Study: 33906005

Group type: EXPERIMENTAL
Intervention: Suicidality assessed using the suicide item of the 17-item Hamilton Depression Rating Scale (HAM-D)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Lower body mass index (BMI)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Higher HAM-D score
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Lower C-reactive protein (CRP) level
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Increased number of inpatient hospitalizations
Number of subjects: 266
Study: 36053969

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg once daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 35
Study: 32747973

Group type: EXPERIMENTAL
Intervention: Casper stents
Number of subjects: 88

Group type: COMPARATOR
Intervention: Closed-cell stents
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 34534410

Group type: EXPERIMENTAL
Intervention: LYR-210 (2500 ?g)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: LYR-210 (7500 ?g)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (saline irrigation only)
Number of subjects: 67
Study: 32130116

Group type: EXPERIMENTAL
Intervention: Digital Health Intervention (DHI)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Educational modules viewed
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tasks completed
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Total log-ins
Number of subjects: 61
Study: 36070357

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injection
Number of subjects: 50
Study: 33458857

Group type: EXPERIMENTAL
Intervention: Random forest method
Number of subjects: 2332

Group type: EXPERIMENTAL
Intervention: Boosted decision tree, support vector machine, nonparametric random forest method, and neural network models
Number of subjects: 2332
Study: 32377675

Group type: EXPERIMENTAL
Intervention: Hybrid-Hyrax
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hyrax
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Keles
Number of subjects: 66
Study: 32236715

Group type: EXPERIMENTAL
Intervention: Glenohumeral injection of triamcinolone 8 weeks postoperatively
Number of subjects: 88

Group type: COMPARATOR
Intervention: No injection postoperatively
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 32186028

Group type: EXPERIMENTAL
Intervention: TwHF cream
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 35174556

Group type: EXPERIMENTAL
Intervention: risankizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: long-term risankizumab
Number of subjects: 0
Study: 35747933

Group type: EXPERIMENTAL
Intervention: Combination of carbohydrate (30g) and protein (15g + 15g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Carbohydrate (30g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Zero-calorie control
Number of subjects: 6
Study: 35378149

Group type: EXPERIMENTAL
Intervention: Zuranolone 30 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 33653769

Group type: EXPERIMENTAL
Intervention: Virtual care with remote automated monitoring (RAM)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 900
Study: 36026800

Group type: EXPERIMENTAL
Intervention: ABP‐051 stimulation therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 62
Study: 34290862

Group type: EXPERIMENTAL
Intervention: Sublingual CoQ10 (400 mg/d)
Number of subjects: 40
Study: 33742481

Group type: EXPERIMENTAL
Intervention: Alcohol infusion
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 37
Study: 32170665

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA with antithrombotic therapy
Number of subjects: 1877

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA without antithrombotic therapy
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Placebo with antithrombotic therapy
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Placebo without antithrombotic therapy
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Any antithrombotic therapy
Number of subjects: 1877

Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 1877
Study: 33431073

Group type: EXPERIMENTAL
Intervention: Psychosis risk calculator using neurocognitive, clinical, medical, and environmental variables
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Children's Global Assessment Scale, delusions of predicting the future, percent married in neighborhood
Number of subjects: 632
Study: 34112582

Group type: EXPERIMENTAL
Intervention: Frailty phenotype (FP) assessment
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Age 70 or older
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Muscle mass
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: HF functional classes I
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: HF functional classes II
Number of subjects: 136
Study: 32112104

Group type: EXPERIMENTAL
Intervention: Insecticide exposure (DDT, pyrethroids, carbamates, organophosphates)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance genes (kdr L1014F, L1014S, N1575Y; ace1 G119S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Environmental and socio-economic factors
Number of subjects: 0
Study: 33741235

Group type: EXPERIMENTAL
Intervention: PhoRTE
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PhoRTE + EMST
Number of subjects: 24
Study: 34915186

Group type: EXPERIMENTAL
Intervention: e-learning group (n=59)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: EDD group (n=53)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (n=55)
Number of subjects: 167
Study: 35782635

Group type: EXPERIMENTAL
Intervention: Training about PBIS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Training plus RS3 (Rural School Support Strategies)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (enhanced condition)
Number of subjects: 40
Study: 32503946

Group type: EXPERIMENTAL
Intervention: ipilimumab 10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: ipilimumab 3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ipilimumab 10 mg/kg (subgroup with asymptomatic brain metastasis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ipilimumab 3 mg/kg (subgroup with asymptomatic brain metastasis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ipilimumab 10 mg/kg (wild-type BRAF tumors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ipilimumab 3 mg/kg (wild-type BRAF tumors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ipilimumab 10 mg/kg (mutant BRAF tumors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ipilimumab 3 mg/kg (mutant BRAF tumors)
Number of subjects: 0
Study: 33467877

Group type: EXPERIMENTAL
Intervention: Presence of DWI lesions
Number of subjects: 466
Study: 33629548

Group type: EXPERIMENTAL
Intervention: T16Ainh‐A01
Number of subjects: 0

Group type: COMPARATOR
Intervention: DMSO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Senescent group (P12)
Number of subjects: 0
Study: 36432453

Group type: EXPERIMENTAL
Intervention: Discontinue central access at an enteral feeding volume of 100 mL/kg/day
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard discontinuation at an enteral feeding volume of 140 mL/kg/day
Number of subjects: 211
Study: 32385918

Group type: EXPERIMENTAL
Intervention: Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Biweekly Gemcitabine and Carboplatin
Number of subjects: 84
Study: 35670748

Group type: EXPERIMENTAL
Intervention: Press tack acupuncture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Press tack placebo
Number of subjects: 72
Study: 35801367

Group type: EXPERIMENTAL
Intervention: Simulation-based flipped classroom (SBFC)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Traditional simulation (TS)
Number of subjects: 326
Study: 33955599

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus androgen deprivation therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo plus androgen deprivation therapy
Number of subjects: 92
Study: 32980559

Group type: EXPERIMENTAL
Intervention: Auriculotherapy (ear seeds placed on shoulder and muscle relaxation points from 2 hours prior to surgery until 24 hours after surgery)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (ear seeds placed on placebo points)
Number of subjects: 90
Study: 36052728

Group type: EXPERIMENTAL
Intervention: VOCs based COVID-19 detection model
Number of subjects: 201
Study: 34028986

Group type: EXPERIMENTAL
Intervention: 131I-MIBG therapy at a dose of 15 mCi/kg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 131I-MIBG + Bu/Mel therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 131I-MIBG therapy at doses of 12, 15, and 18 mCi/kg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 131I-MIBG therapy
Number of subjects: 68
Study: 32234531

Group type: EXPERIMENTAL
Intervention: Limiting portions of problem foods
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Pre-portioned foods
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Avoidance strategies for problem foods
Number of subjects: 186
Study: 35551084

Group type: EXPERIMENTAL
Intervention: Electronic medical record (EMR) based paediatric asthma pathway, online learning modules, in‐person training for allied health teams in asthma education, and a clinical dashboard for patient management.
Number of subjects: 37
Study: 34400339

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 160 ppm for 30 min twice daily
Number of subjects: 29
Study: 35144945

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) 4-factor (15 IU/kg)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP) (10 mL/kg)
Number of subjects: 594
Study: 33971951

Group type: EXPERIMENTAL
Intervention: Simple cognitive task intervention (memory cue + mental rotation instructions + computer game 'Tetris' for at least 20 min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (podcast, similar time)
Number of subjects: 16
Study: 33150554

Group type: EXPERIMENTAL
Intervention: Clarifying dialogue
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Key information mentioned first
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chronological order
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unidirectional information exchange
Number of subjects: 80
Study: 32166877

Group type: EXPERIMENTAL
Intervention: Azithromycin alongside seasonal malaria chemoprevention (sulfadoxine-pyrimethamine plus amodiaquine)
Number of subjects: 19578

Group type: COMPARATOR
Intervention: Placebo alongside seasonal malaria chemoprevention (sulfadoxine-pyrimethamine plus amodiaquine)
Number of subjects: 19578
Study: 33920488

Group type: EXPERIMENTAL
Intervention: Parental feeding practices (monitoring, pressure to eat, restriction)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Parental perception of children's weight
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Health education for parents
Number of subjects: 316
Study: 34363942

Group type: EXPERIMENTAL
Intervention: Discontinuing antibiotic therapy
Number of subjects: 467

Group type: COMPARATOR
Intervention: Usual strategy of continuing antibiotic treatment
Number of subjects: 467
Study: 33618685

Group type: EXPERIMENTAL
Intervention: Mobile application (Dental Surgical Forceps application version 2.1.0.0)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no mobile application)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Mobile application
Number of subjects: 67
Study: 33559021

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS)
Number of subjects: 39
Study: 32390729

Group type: EXPERIMENTAL
Intervention: Three-week soleus stretch (knee flexed) and gastrocnemius stretch (knee extended)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no stretching intervention)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 33
Study: 35615439

Group type: EXPERIMENTAL
Intervention: ICD/CRT-D implantation with remote management
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine intervention (Control group)
Number of subjects: 60
Study: 34380747

Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light chain (NfL) levels measured in ALS cases within 5 years of diagnosis
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light chain (NfL) levels measured in ALS cases further away from diagnosis
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Correlation of metabolites with pre‐diagnostic NfL levels in ALS cases
Number of subjects: 84
Study: 36449307

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 7.5 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 15 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 30 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 33832658

Group type: EXPERIMENTAL
Intervention: Intragastric balloons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle interventions
Number of subjects: 0
Study: 32998769

Group type: EXPERIMENTAL
Intervention: Higher PEEP (6-8 cmH2O)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Lower PEEP (3-5 cmH2O)
Number of subjects: 216
Study: 33739852

Group type: EXPERIMENTAL
Intervention: Intensified pegaspargase (four additional doses at 3-week intervals during consolidation and interim maintenance)
Number of subjects: 1857

Group type: COMPARATOR
Intervention: Standard COG low-intensity therapy (including two pegaspargase doses during induction and delayed intensification)
Number of subjects: 1857

Group type: COMPARATOR
Intervention: Low-risk patients (with favorable cytogenetics) compared to standard-risk patients (with identical therapy but without favorable or unfavorable cytogenetics)
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for intensified pegaspargase
Number of subjects: 1857

Group type: COMPARATOR
Intervention: Overall survival (OS) for standard COG therapy
Number of subjects: 1857